|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 1/23/2017 6:07:22 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Adventitious Presence (Low Level Presence)
---International Low Level Presence Policies
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchrony Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Labeling
---S. 2634: The One Health Act
Potential Regulation of New Genetic Modification Technologies
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
Review of the Federal Coordinated Framework for Biotechnology Products
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
OMara |
|
|
|
Rina |
Singh |
|
|
|
Tom |
Dilenge |
|
|
|
Sarah |
Kyle |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Labeling
---S. 2634: The One Health Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sarah |
Kyle |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Funding for Biofuels
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for FY 2017
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5293/S.3000: Department of Defense Appropriations Act for FY 2017
Funding for FDA
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Funding for Renewable Chemicals/Bio-based Products
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for FY 2017
---H.R. 5293/S.3000: Department of Defense Appropriations Act for FY 2017
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
|
Tracey |
LaTurner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for FY 2017
---H.R. 5293/S.3000: Department of Defense Appropriations Act for FY 2017
Renewable Chemicals/Bio-based Products (Non-Funding)
---Expansion of Master Limited Partnerships to Renewable Chemicals
---Investment Tax Credit for Renewable Chemicals and Bio-based Products
---New Production Tax Credit
---Reauthorization of USDA Bio-Preferred Program
---S. 1656/H.R. 2883: Master Limited Partnership Parity Act
---S. 2271: The Renewable Chemical Production Tax Credit Act
---H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Biosimilars
---Access to Samples for Testing
---Biosimilar User Fee Act Reauthorization and Implementation
---Brazil Biologics Regulations
---Coding
---Colombia Biologics Regulations
---Implementation of Affordable Care Act
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
---CREATES Act (House Energy & Commerce Committee Discussion Draft)
Drug Importation
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Labeling
---S. 2634: The One Health Act
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Nicolas |
Magallanes |
|
|
|
Tom |
Dilenge |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Drug Patent Settlements
---S. 2019: Preserve Access to Affordable Generics Act of 2015
Inter Partes Review
---H.R.5485-S.3067: Financial Services and General Government Appropriations Act for FY 2017
---Implementation of the America Invents Act of 2011
---S.1137: The PATENTS Act of 2015
Patent Reform
---H.R. 9: Innovation Act
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
UN High Level Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
Rep. Whitfield Chief of Staff, 11-1-2014-10-21-2016; LD 1-1-2013- 11-1-2014; LA 2-1-2011- 1-1-2013; LA Sen. LeMieux, 9-1-2009- 1-1-2011; Sen. Martinez, Research Asst. 2-1-2009- 9-1-2009; LC 8-1-2008- 2-1-2009; Staff Asst. 4-1-2008 to 8-1-2008 |
|
Tom |
Dilenge |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Production Tax Credit Extension
Cartagena Biosafety Protocol
---Nagoya Protocol on Access and Benefit sharing
Funding for Biofuels
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for FY 2017
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5293/S.3000: Department of Defense Appropriations Act for FY 2017
Renewable Fuel Standard
---EPA Proposed Rule for the Renewable Fuel Standard Program: Standards for 2017 and Biomass-Based Diesel Volume for 2018
---H.R. 1736/S. 1239: To amend the Clean Air Act with respect to the ethanol waiver for the Reid vapor pressure limitations under such Act
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Efficient Science-Based Review of Biotech Products
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Labeling
---S. 2634: The One Health Act
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
Dilenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Production Tax Credit Extension
Cartagena Biosafety Protocol
---Nagoya Protocol on Access and Benefit sharing
Funding for Biofuels
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for FY 2017
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5293/S.3000: Department of Defense Appropriations Act for FY 2017
Renewable Fuel Standard
---EPA Proposed Rule for the Renewable Fuel Standard Program: Standards for 2017 and Biomass-Based Diesel Volume for 2018
---H.R. 1736/S. 1239: To amend the Clean Air Act with respect to the ethanol waiver for the Reid vapor pressure limitations under such Act
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures/ Senate Innovation for Healthier Americans
---H.R.34: 21st Century Cures Act
---Biomarkers and Regulatory Science Improvements
---Communication with Healthcare Professionals and Payors
---Expanded Access to Investigational Drugs
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---Innovation Incentives
---Longitudinal Study of Chronic Diseases
---Patient Access to Approved Drugs
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Use of Real-World Evidence
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---S. 1878: Advancing Hope Act of 2015
---S. 195: PATH Act
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act of 2015
---S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act
---S. 524: Comprehensive Addiction and Recovery Act of 2016
---H.R. 4762: Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act
---S. 3239/H.R. 5858: RACE for Children Act
340B Drug Pricing Program
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Implementation of Affordable Care Act
---Program Implementation & Oversight
Biodefense Research, Development and Procurement Issues (Non-Funding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act of 2015
Biosimilars
---Access to Samples for Testing
---Biosimilar User Fee Act Reauthorization and Implementation
---Brazil Biologics Regulations
---Coding
---Colombia Biologics Regulations
---Implementation of Affordable Care Act
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
---CREATES Act (House Energy & Commerce Committee Discussion Draft)
Drug Evaluation and Review
---Implementation of the FDA Safety and Innovation Act
---Reauthorization of the Prescription Drug User Fee Act
---ADAPT Act (House Discussion Draft)
---Compassionate Use/Expanded Access
---H.R. 2029: The Patient Choice Act
---H.R. 4475: Compassionate Freedom of Choice Act
---S. 2912: Trickett Wendler Right to Try Act of 2016
Drug Importation
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Drug Manufacturing, Quality & Distribution
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Vial and Dose Size
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for FDA
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Gene Editing Technologies
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Generic Drug Entry
---CREATES Act (House Energy & Commerce Committee Discussion Draft)
---S. 2615: Increasing Competition in Pharmaceuticals Act
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
Independent Payment Advisory Board
Orphan Drug Act Tax Credit
Precision Medicine Initiative
Reimbursement for Innovative Products
---CMMI Medicare Part B Proposed Demonstration Project
---Medicare Part B Physician-Administered Products
---Value-based Contracting and Communications
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
UN High Level Commission on Access to Medicines
Vaccines and Infectious Diseases
---H.R. 3299: Strengthening Public Health Emergency Response Act
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act
---Supplemental Funding for Combating Zika
---Vaccine Injury Compensation Program
---Vaccine Safety
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Kathleen |
Holcombe |
|
|
|
Matthew |
OMara |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tom |
Dilenge |
|
|
|
Scott |
McGoohan |
|
|
|
Taylor |
Booth |
|
Rep. Whitfield Chief of Staff,11-1-2014-10-21-2016; LD 1-1-2013- 11-1-2014; LA 2-1-2011- 1-1-2013; LA Sen. LeMieux, 9-1-2009- 1-1-2011; Sen. Martinez, Research Asst. 2-1-2009- 9-1-2009; LC 8-1-2008- 2-1-2009; Staff Asst. 4-1-2008 to 8-1-2008 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-Funding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act of 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
21st Century Cures/ Senate Innovation for Healthier Americans
---H.R. 34: The 21st Century Cures Act
---Longitudinal Study of Chronic Diseases
Biodefense Research, Development and Procurement Issues (Non-Funding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act of 2015
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Funding for National Institutes of Health
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---H.R.5325: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act for 2017, and Zika Response and Preparedness Act
---Supplemental Funding for Combating Zika
Gene Editing Technologies
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Precision Medicine Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures/ Senate Innovation for Healthier Americans
---H.R. 34: The 21st Century Cures Act
---Patient Access to Approved Drugs
Reimbursement for Innovative Products
---CMMI Medicare Part B Proposed Demonstration Project
---Medicare Part B Physician-Administered Products
---Value-based Contracting and Communications
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Nicolas |
Magallanes |
|
|
|
Sarah |
Kyle |
|
|
|
Tom |
Dilenge |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Investment Incentives
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 341: Start-up Jobs and Innovation Act
---S. 537: COMPETE Act
---H.R. 2179: PARTNER Act
Capital Market Enhancements
---Financial CHOICE Act (House Discussion Draft)
---H.R. 1675/S. 576: Encouraging Employee Ownership Act
---H.R. 1675: Capital Markets Improvement Act
---H.R. 2187: Fair Investment Opportunities for Professional Experts Act
---H.R. 2354: Streamlining Excessive and Costly Regulations Review Act
---H.R. 2357: Accelerating Access to Capital Act
---H.R. 3784/S.2867: Securities & Exchange Commission Small Business Advocate Act
---H.R. 4168: Small Business Capital Formation Enhancement Act
---H.R. 4638: Main Street Growth Act
---H.R. 6427: Creating Financial Prosperity for Businesses and Investors Act
---PCAOB Audit Cost Increases
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
---Financial CHOICE Act (House Discussion Draft)
---H.R. 5311: Corporate Governance Reform and Transparency Act
---Impact of Policies on Small Public Companies
Proxy Advisory Services
---Financial CHOICE Act (House Discussion Draft)
---H.R. 5311: Corporate Governance Reform and Transparency Act
---Impact of Policies on Small Public Companies
Reform of SEC Regulation D
---Financial CHOICE Act (House Discussion Draft)
---H.R. 4498/S. 978: HALOS Act
Sarbanes Oxley Section 404 (b)
---Financial CHOICE Act (House Discussion Draft)
---H.R. 4139: Fostering Innovation Act
---PCAOB Audit Cost Increases
---Small Issuer Exemption
Short Selling Transparency
---H.R.5485-S.3067: Financial Services and General Government Appropriations Act for FY 2017
Stock Exchange Tick Size
XBRL Exemption for Small Public Companies
---Financial CHOICE Act (House Discussion Draft)
---H.R. 1675: Capital Markets Improvement Act
---H.R. 1965: Small Company Disclosure Simplification Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Jeanne |
Haggerty |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels (Non-Funding)
---Production Tax Credit Extension
Capital Formation Investment Incentives
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 341: Start-up Jobs and Innovation Act
---H.R. 2179: PARTNER Act
---S. 537: COMPETE Act
Inversions
---H.R.5485-S.3067: Financial Services and General Government Appropriations Act for FY 2017
Treatment of Financial Interests as Stock or Indebtedness
---Section 385 Proposed Regulations
Orphan Drug Act Tax Credit
No sub-issues
Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit for Renewable Chemicals and Bio-based Products
---New Production Tax Credit
---H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
---S. 2271: The Renewable Chemical Production Tax Credit Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Biosimilars
---Brazil Biologics Regulations
---Colombia Biologics Regulations
---India Biologics Regulations
---Mexico Biologics Regulations
Drug Importation
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R. 5926/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchrony Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
UN High Level Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Kathleen |
Holcombe |
|
|
|
Matthew |
OMara |
|
|
|
Nicolas |
Magallanes |
|
|
|
Tom |
Dilenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
4 |
|
||||||
| 2 |
|
5 |
|
||||||
| 3 |
|
6 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |